文献速递系统性红斑狼疮

系统性红斑狼疮或糖尿病医疗补助受益者及一般医疗补助人群的血脂检测与他汀类处方

Lipid Testing and Statin Prescriptions Among Medicaid Recipients With Systemic Lupus Erythematosus or Diabetes Mellitus and the General Medicaid Population.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2019-01-01

研究利用2007—2010年29个州的医疗补助数据,比较了25,950例系统性红斑狼疮(SLE)、51,900例糖尿病(DM)及103,800例无这两种疾病的医疗补助人群接受血脂检测和他汀类处方的比例。SLE组血脂检测(24%)和他汀处方(11%)均低于DM组(43%、33%)和一般人群(16%、7%)。与DM患者相比,SLE患者接受血脂检测的比值比为0.34(95%CI 0.34-0.35),填写他汀处方的比值比为0.18(95%CI 0.18-0.18)。

要点

  • SLE患者血脂检测比例24%,低于DM患者43%和一般医疗补助人群16%。
  • SLE患者他汀处方比例11%,低于DM患者33%和一般医疗补助人群7%。
  • 与DM患者相比,SLE患者接受血脂检测的OR为0.34,他汀处方的OR为0.18。

核心结论

  • 尽管SLE患者心血管疾病风险升高,但其接受血脂检测和他汀类处方的比例低于年龄和性别匹配的DM患者及一般医疗补助人群,这一差距应作为改善目标。

研究设计与样本

  • 利用2007—2010年29个州的Analytic eXtract文件,识别18—65岁美国医疗补助受益者中 prevalent SLE 队列,按年龄和性别与2例DM患者及4例无SLE或DM的一般医疗补助个体匹配,比较1年随访期间接受至少1次血脂检测和至少1次他汀处方的比例。

主要发现

  • 共纳入25,950例SLE患者、51,900例DM患者和103,800例无这两种疾病的一般医疗补助个体。
  • 血脂检测在SLE组为24%,DM组为43%,无这两种疾病组为16%。
  • 他汀处方在SLE组为11%,DM组为33%,无这两种疾病组为7%。
  • 与DM患者相比,SLE患者接受血脂检测的OR为0.34(95%CI 0.34-0.35),填写他汀处方的OR为0.18(95%CI 0.18-0.18)。
  • 与一般医疗补助人群相比,SLE患者填写他汀处方的OR为0.89(95%CI 0.84-0.94)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cardiovascular disease (CVD) risks in systemic lupus erythematosus (SLE) are similar to those in diabetes mellitus (DM). We investigated whether the numbers of lipid tests and statin prescriptions in patients with SLE are comparable with those in patients with DM and those in individuals without either disease. METHODS: Using Analytic eXtract files from 29 states for 2007-2010, we identified a cohort of US Medicaid beneficiaries, ages 18-65 years, with prevalent SLE. Each SLE patient was matched for age and sex with 2 patients with DM and 4 individuals in the general Medicaid population who did not have either SLE or DM. We compared the proportions of patients in each cohort who received ≥1 lipid test and ≥1 statin prescription during 1-year follow-up. We used multivariable logistic regression to calculate the odds of lipid testing and receiving prescriptions for statins and conditional logistic regression to compare the matched cohorts. RESULTS: We identified 3 Medicaid cohorts: 25,950 patients with SLE, 51,900 patients with DM, and 103,800 Medicaid recipients without either condition. In these cohorts, lipid testing was performed in 24% of patients in the SLE group, 43% of patients in the DM group, and 16% of individuals in the group with neither condition, and statin prescriptions were dispensed in 11%, 33%, and 7% of these groups, respectively. SLE patients were 66% less likely (odds ratio [OR] 0.34, 95% confidence interval [95% CI] 0.34-0.35) to have lipid tests and 82% less likely (OR 0.18, 95% CI 0.18-0.18) to fill a statin prescription compared with DM patients. SLE patients were also less likely (OR 0.89, 95% CI 0.84-0.94) to fill a statin prescription compared with individuals in the general Medicaid population. CONCLUSION: Despite having an elevated risk of CVD, SLE patients received less lipid testing and received fewer statin prescriptions compared with age- and sex-matched DM patients and individuals in the general Medicaid population; this gap should be a target for improvement.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Chen SK, Barbhaiya M, Fischer MA, et al. Lipid Testing and Statin Prescriptions Among Medicaid Recipients With Systemic Lupus Erythematosus or Diabetes Mellitus and the General Medicaid Population. Arthritis Care Res (Hoboken). 2019. PMID: 29648687. doi:10.1002/acr.23574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。